Ultragenyx pauses antisense trial after patients lose ability to walk

Ultragenyx Pharmaceutical has paused dosing in a phase 1/2 trial of a rare disease drug after patients temporarily lost the ability to walk. All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study and plan to amend dosing.